{"entity":{"id":"fnr-uruguay","kind":"institution","name":"Fondo Nacional de Recursos (Uruguay)","aka":["FNR","FNR Uruguay","National Resource Fund of Uruguay"],"tldr":"Uruguay's national fund for high-cost care. It pays for specialised procedures and, since 2005, for high-cost medicines on the national formulary, including cancer medicines such as trastuzumab, pembrolizumab and osimertinib, for everyone covered by the national health system.","summary":"The Fondo Nacional de Recursos began work on 1 December 1980 under Decreto-Ley 14.897, by its history page (another of its pages says 1981), and is now governed by Ley 16.343 of 24 December 1992. It is a non-state public body run by an honorary board of nine: three ministry of health representatives, with the minister in the chair, and members for social security, the economy ministry, the comprehensive care providers and the specialised institutes. It acts as a reinsurer for the providers: it gives universal financial cover for high-complexity procedures, devices and high-cost medicines to everyone with cover through the national health system. Most of its income is a fixed monthly quota for each FONASA contributor, transferred by social security; the economy ministry reimburses the cost for public-system patients who do not contribute. Its offices are at La Cumparsita 1373, Montevideo; the coordinates are approximate.\n\nArticle 313 of the 2005 budget law, Ley 17.930, added high-cost medicines to its cover, starting with tyrosine kinase inhibitors for leukaemia and GIST, rituximab for non-Hodgkin lymphoma, and trastuzumab and fulvestrant for breast cancer; its 2023 annual report says cetuximab for colon cancer and daratumumab for myeloma were added more recently (it prints the year as \"20223\", so 2022 or 2023), and that it authorised 4,980 new medicine treatments for all conditions in 2023. Its pages list cover for breast cancer (fulvestrant, lapatinib, pertuzumab, trastuzumab emtansine, trastuzumab, ribociclib and pembrolizumab), for which it authorised 714 treatment requests in 2025, and for lung cancer (erlotinib, gefitinib, osimertinib, alectinib, atezolizumab, atezolizumab with bevacizumab and pembrolizumab). Under article 462 of Ley 19.355 (2015), adding a medicine it will fund to the national formulary requires a prior technical report from representatives of the Faculty of Medicine, the medical profession, the ministry and the fund. It is also a Cochrane collaborating centre for Uruguay.","asOf":"2026-11-11","links":[{"label":"FNR: what the Fondo Nacional de Recursos is","url":"https://www.fnr.gub.uy/que-es-el-fondo-nacional-de-recursos/"},{"label":"FNR: history","url":"https://www.fnr.gub.uy/historia/"},{"label":"FNR: treatments with medicines","url":"https://www.fnr.gub.uy/tratamientos_medicamentos/"},{"label":"FNR: October, breast cancer prevention month (2025 authorisations)","url":"https://www.fnr.gub.uy/noticia_slide/octubre-rosa-2026/"},{"label":"FNR: annual report 2023 (PDF)","url":"https://www.fnr.gub.uy/wp-content/uploads/2024/11/memoria_2023.pdf"},{"label":"IMPO: Ley 16.343 (24 December 1992)","url":"https://www.impo.com.uy/bases/leyes/16343-1992"}],"tags":[],"related":["global-oncology-access"],"cancers":["breast-cancer","lung-cancer","colorectal","prostate","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","pertuzumab","fulvestrant","ribociclib","pembrolizumab","osimertinib","cetuximab","daratumumab","imatinib","rituximab"],"companies":[],"institutions":["msp-uruguay"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montevideo","country":"UY","lat":-34.904,"lng":-56.188,"institutionType":"government","website":"https://www.fnr.gub.uy","programs":["High-cost medicines (from 2005)","Specialised procedures in the Institutos de Medicina Altamente Especializada","PET scanning and bone marrow transplantation","Tobacco dependence treatment","Cochrane collaborating centre for Uruguay"]},"route":"/institutions/fnr-uruguay/","neighbours":{"technology":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"msp-uruguay","kind":"institution","name":"Ministerio de Salud Pública (Uruguay)","route":"/institutions/msp-uruguay/"}]}}